ASX - By Stock
|
AVR |
Re:
Proactive vid
|
|
redant
|
45 |
17K |
2 |
09/05/23 |
09/05/23 |
ASX - By Stock
|
45
|
17K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Proactive vid
|
|
redant
|
45 |
17K |
6 |
08/05/23 |
08/05/23 |
ASX - By Stock
|
45
|
17K
|
6
|
|
ASX - By Stock
|
TD1 |
Akili Latest
|
|
redant
|
14 |
6.9K |
3 |
04/05/23 |
04/05/23 |
ASX - By Stock
|
14
|
6.9K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
AGM questions for submission to management
|
|
redant
|
37 |
16K |
2 |
02/05/23 |
02/05/23 |
ASX - By Stock
|
37
|
16K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Proactive vid
|
|
redant
|
45 |
17K |
0 |
01/05/23 |
01/05/23 |
ASX - By Stock
|
45
|
17K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Proactive vid
|
|
redant
|
45 |
17K |
0 |
01/05/23 |
01/05/23 |
ASX - By Stock
|
45
|
17K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Proactive vid
|
|
redant
|
45 |
17K |
0 |
01/05/23 |
01/05/23 |
ASX - By Stock
|
45
|
17K
|
0
|
|
ASX - By Stock
|
AVR |
Update on Edwards
|
|
redant
|
1 |
867 |
1 |
28/04/23 |
28/04/23 |
ASX - By Stock
|
1
|
867
|
1
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Two new deoxymab patents granted in the USA
|
|
redant
|
20 |
11K |
2 |
27/04/23 |
27/04/23 |
ASX - By Stock
|
20
|
11K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
redant
|
16 |
7.2K |
0 |
24/04/23 |
24/04/23 |
ASX - By Stock
|
16
|
7.2K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
redant
|
16 |
7.2K |
3 |
24/04/23 |
24/04/23 |
ASX - By Stock
|
16
|
7.2K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Agreement to Develop New Heart Valve Repair Device
|
|
redant
|
34 |
13K |
0 |
19/04/23 |
19/04/23 |
ASX - By Stock
|
34
|
13K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Agreement to Develop New Heart Valve Repair Device
|
|
redant
|
34 |
13K |
3 |
19/04/23 |
19/04/23 |
ASX - By Stock
|
34
|
13K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Agreement to Develop New Heart Valve Repair Device
|
|
redant
|
34 |
13K |
8 |
19/04/23 |
19/04/23 |
ASX - By Stock
|
34
|
13K
|
8
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Updated guidance for PAT-DX1 phase 1 clinical study
|
|
redant
|
125 |
48K |
8 |
13/04/23 |
13/04/23 |
ASX - By Stock
|
125
|
48K
|
8
|
|
ASX - By Stock
|
AN1 |
Re:
Ann: Application for quotation of securities - AN1
|
|
redant
|
2 |
1.0K |
1 |
05/04/23 |
05/04/23 |
ASX - By Stock
|
2
|
1.0K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Updated guidance for PAT-DX1 phase 1 clinical study
|
|
redant
|
125 |
48K |
3 |
05/04/23 |
05/04/23 |
ASX - By Stock
|
125
|
48K
|
3
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Updated guidance for PAT-DX1 phase 1 clinical study
|
|
redant
|
125 |
48K |
4 |
05/04/23 |
05/04/23 |
ASX - By Stock
|
125
|
48K
|
4
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Updated guidance for PAT-DX1 phase 1 clinical study
|
|
redant
|
125 |
48K |
1 |
05/04/23 |
05/04/23 |
ASX - By Stock
|
125
|
48K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Updated guidance for PAT-DX1 phase 1 clinical study
|
|
redant
|
125 |
48K |
1 |
04/04/23 |
04/04/23 |
ASX - By Stock
|
125
|
48K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Updated guidance for PAT-DX1 phase 1 clinical study
|
|
redant
|
125 |
48K |
1 |
04/04/23 |
04/04/23 |
ASX - By Stock
|
125
|
48K
|
1
|
|
ASX - By Stock
|
AN1 |
Expiry of Options - AN1OA
|
|
redant
|
2 |
933 |
2 |
04/04/23 |
04/04/23 |
ASX - By Stock
|
2
|
933
|
2
|
|
ASX - By Stock
|
TD1 |
Re:
Ann: TGA approval of ReadyAttentionGo!
|
|
redant
|
21 |
7.9K |
6 |
29/03/23 |
29/03/23 |
ASX - By Stock
|
21
|
7.9K
|
6
|
|
ASX - By Stock
|
TD1 |
Re:
Ann: TGA approval of ReadyAttentionGo!
|
|
redant
|
21 |
7.9K |
0 |
29/03/23 |
29/03/23 |
ASX - By Stock
|
21
|
7.9K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: FDA Allows Manufacturing to Begin at Expanded Facility
|
|
redant
|
7 |
4.5K |
3 |
27/03/23 |
27/03/23 |
ASX - By Stock
|
7
|
4.5K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
consolidation dates and details
|
|
redant
|
4 |
2.4K |
0 |
26/03/23 |
26/03/23 |
ASX - By Stock
|
4
|
2.4K
|
0
|
|
ASX - By Stock
|
ICN |
Re:
Ann: Half Yearly Report and Accounts
|
|
redant
|
10 |
3.3K |
1 |
22/03/23 |
22/03/23 |
ASX - By Stock
|
10
|
3.3K
|
1
|
|
ASX - By Stock
|
ICN |
Re:
Ann: Suspension from Quotation
|
|
redant
|
5 |
2.5K |
1 |
17/03/23 |
17/03/23 |
ASX - By Stock
|
5
|
2.5K
|
1
|
|
ASX - By Stock
|
ICN |
Re:
Ann: Suspension from Quotation
|
|
redant
|
5 |
2.5K |
0 |
17/03/23 |
17/03/23 |
ASX - By Stock
|
5
|
2.5K
|
0
|
|
ASX - By Stock
|
ICN |
Re:
Ann: Quarterly Activities/Appendix 5B Cash Flow Report
|
|
redant
|
10 |
4.7K |
0 |
15/03/23 |
15/03/23 |
ASX - By Stock
|
10
|
4.7K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
DurAVR THV FIH Clinical Update at CRT 23
|
|
redant
|
9 |
5.0K |
0 |
08/03/23 |
08/03/23 |
ASX - By Stock
|
9
|
5.0K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Settlement of $35M Capital Raising Transaction
|
|
redant
|
205 |
69K |
0 |
06/03/23 |
06/03/23 |
ASX - By Stock
|
205
|
69K
|
0
|
|
ASX - By Stock
|
AVR |
Abbot Article
|
|
redant
|
11 |
3.7K |
22 |
02/03/23 |
02/03/23 |
ASX - By Stock
|
11
|
3.7K
|
22
|
|
ASX - By Stock
|
PAB |
Re:
Ann: Appendix 4D - Half Year Accounts - 31 December 2022
|
|
redant
|
37 |
13K |
2 |
28/02/23 |
28/02/23 |
ASX - By Stock
|
37
|
13K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Settlement of $35M Capital Raising Transaction
|
|
redant
|
205 |
69K |
1 |
26/02/23 |
26/02/23 |
ASX - By Stock
|
205
|
69K
|
1
|
|
ASX - By Stock
|
AVR |
Re:
New proactive vid
|
|
redant
|
18 |
6.7K |
2 |
17/02/23 |
17/02/23 |
ASX - By Stock
|
18
|
6.7K
|
2
|
|
ASX - By Stock
|
AVR |
Medtronics
|
|
redant
|
1 |
698 |
3 |
14/02/23 |
14/02/23 |
ASX - By Stock
|
1
|
698
|
3
|
|
ASX - By Stock
|
AVR |
Re:
Ann: $35M Capital Raise
|
|
redant
|
147 |
39K |
6 |
13/02/23 |
13/02/23 |
ASX - By Stock
|
147
|
39K
|
6
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Trading Halt
|
|
redant
|
53 |
18K |
0 |
07/02/23 |
07/02/23 |
ASX - By Stock
|
53
|
18K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Proposed $50 Million Capital Facility
|
|
redant
|
62 |
18K |
0 |
06/02/23 |
06/02/23 |
ASX - By Stock
|
62
|
18K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Trading Halt
|
|
redant
|
78 |
27K |
0 |
06/02/23 |
06/02/23 |
ASX - By Stock
|
78
|
27K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Ann: Trading Halt
|
|
redant
|
78 |
27K |
2 |
06/02/23 |
06/02/23 |
ASX - By Stock
|
78
|
27K
|
2
|
|
ASX - By Stock
|
AVR |
Re:
The latent value in the Adapt treatment process.
|
|
redant
|
30 |
12K |
2 |
28/01/23 |
28/01/23 |
ASX - By Stock
|
30
|
12K
|
2
|
|
ASX - By Stock
|
ICN |
Re:
Ann: Response to ASX Price Query
|
|
redant
|
3 |
1.8K |
0 |
23/01/23 |
23/01/23 |
ASX - By Stock
|
3
|
1.8K
|
0
|
|
ASX - By Stock
|
AVR |
Re:
Competitor FDA approval
|
|
redant
|
18 |
8.3K |
2 |
20/01/23 |
20/01/23 |
ASX - By Stock
|
18
|
8.3K
|
2
|
|
ASX - By Stock
|
TD1 |
Re:
akili
|
|
redant
|
146 |
62K |
1 |
18/01/23 |
18/01/23 |
ASX - By Stock
|
146
|
62K
|
1
|
|
ASX - By Stock
|
PAB |
Re:
PAB TOP Holders
|
|
redant
|
140 |
64K |
3 |
18/01/23 |
18/01/23 |
ASX - By Stock
|
140
|
64K
|
3
|
|
ASX - By Stock
|
AVR |
Re:
3D printed heart valves
|
|
redant
|
28 |
10K |
5 |
04/01/23 |
04/01/23 |
ASX - By Stock
|
28
|
10K
|
5
|
|
ASX - By Stock
|
AVR |
Re:
Ann: DurAVR FIH 30-Day Study Results Presented at TCT Boston
|
|
redant
|
11 |
5.4K |
6 |
18/12/22 |
18/12/22 |
ASX - By Stock
|
11
|
5.4K
|
6
|
|
ASX - By Stock
|
PAB |
Re:
PAB Chart & TA
|
|
redant
|
348 |
132K |
6 |
17/12/22 |
17/12/22 |
ASX - By Stock
|
348
|
132K
|
6
|
|